Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Abeona Therapeutics, maintaining a price target of $18.
October 29, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Abeona Therapeutics, maintaining a price target of $18.
The reiteration of an Overweight rating and a maintained price target of $18 by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Abeona Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100